Re-irradiation plus hyperthermia yields 94% complete response in recurrent breast cancer

Re-irradiation plus regional or capacitive hyperthermia achieved 94% complete response across 17 breast cancer recurrences with no grade ≥3 toxicity.

KEY POINTS

  • This retrospective single-center series included 15 patients with 17 locoregional breast cancer recurrences arising in previously irradiated fields. Median age was 64 years, and the median interval between initial treatment and recurrence was 7.3 years.
  • Re-irradiation was delivered with IMRT or VMAT to a median dose of 50 Gy (range 20–66 Gy), usually with fractions of 1.8–2.7 Gy. Hyperthermia followed RT within approximately 10–60 minutes, typically once or twice weekly, with a median of 7 sessions.
  • Six patients received regional hyperthermia, eight received capacitive hyperthermia, and one received both. Among regional hyperthermia treatments, median maximum measured skin temperature was 40.7°C, while direct temperature monitoring was not available for capacitive treatments.
  • At approximately two months after treatment, 16 of 17 lesions (94%) achieved complete response. One lesion showed progressive disease without an initial response.
  • With median follow-up of 30.1 months, two patients developed subsequent locoregional progression, both at approximately 12 months. Estimated 2-year progression-free survival was 75%, while estimated 3-year distant metastasis-free survival was 46%.
  • Treatment was highly multimodal: 15 of 17 lesions underwent surgery before re-irradiation plus hyperthermia, including 11 R0 and four R1 resections, while 14 of 15 patients (93%) also received systemic therapy. The observed outcomes therefore cannot be attributed specifically to hyperthermia or re-irradiation.
  • Toxicity was limited despite prior irradiation. Seven patients had Grade 1 acute toxicity and one had Grade 2 erythema; late toxicity consisted only of Grade 1 events in four patients. No Grade ≥3 acute or late toxicity and no treatment interruption due to toxicity were reported.

CLINICAL TAKEAWAY

Regional or capacitive hyperthermia combined with re-irradiation appears technically feasible in selected patients with locoregional breast cancer recurrence in previously irradiated tissue, including cases requiring deeper or larger-volume heating. The 94% complete-response rate is notable, but the cohort is extremely small and heavily confounded by surgery and systemic therapy, making these findings hypothesis-generating rather than evidence for a specific salvage standard.

SOURCE

Radiation Oncology

Browse more research Suggest a correction